While COVID-19 and its associated vaccines dominated news headlines in 2020, the last twelve months have been notable for significant progress in the world of healthcare.
Figures published recently by the European Medicines Agency (EMA) show an almost 50 per cent increase during 2020 for marketing authorisation recommendations for new medicines compared to the same period in 2019 (97 new medicines compared to 66 the previous year).
Of these 97 medicines, 39 contained new, active substances which had never been authorised in the European Union before.
As well as the high-profile recommendation for the approval of the Pfizer/BioNTech COVID-19 vaccine, the EMA gave the green light to a range of medicines that represented significant progress in their respective therapeutic areas designed to treat cancers, HIV, and rare metabolic disorders like metachromatic leukodystrophy and MCL.
Meanwhile, in the United States, the Food and Drug Administration (FDA) recorded a 10 per cent increase in approvals for new medicines during 2020 (53 compared to 48 in 2019).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.